Literature DB >> 30606739

Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy.

Yi-Ming Chen1,2,3,4, Wen-Nan Huang1,3, Tsai-Ling Liao2,4, Jun-Pen Chen2, Sheng-Shun Yang3,5, Hsin-Hua Chen1,2,3,4, Tsu-Yi Hsieh1, Wei-Ting Hung1, Yi-Hsing Chen6,3, Der-Yuan Chen7,8.   

Abstract

Entities:  

Keywords:  DMARDs (biologic); DMARDs (synthetic); infections; rheumatoid arthritis

Year:  2019        PMID： 30606739     DOI： 10.1136/annrheumdis-2018-214400

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  2 in total

1.  Characterization of Patients with COVID-19 Admitted to a Community Hospital of East Harlem in New York City.

Authors:  Ahmed Shady; Ajay P Singh; Ejiro Gbaje; Marlon Oliva; Samantha Golden-Espinal; Dylan Macciola; Dyanna Soto; William E Eddy; Anusha Adkoli; Nora V Bergasa
Journal:  Cureus       Date:  2020-08-18

Review 2.  Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review.

Authors:  Jose María Álvaro-Gracia; Jose Francisco García-Llorente; Mónica Valderrama; Susana Gomez; Maria Montoro
Journal:  Rheumatol Ther       Date:  2020-11-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.